Experimental drug NU-9 — a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) — improves neuron health in animal models of Alzheimer’s disease, according to a new Northwestern University study.
Like ALS, Alzheimer’s disease also results from misfolded proteins that damage brain health. Rather than treating symptoms from specific diseases, NU-9 instead addresses the underlying…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply